EUVIMEDObjevte EUVIMED
CrossrefInformační karta

TDP‐43 Phosphorylation: Pathological Modification or Protective Factor Antagonizing TDP‐43 Aggregation in Neurodegenerative Diseases?

Simone Mosna, Dorothee Dormann

BioEssays · 2026-01 · 48 (1)

DOI: 10.1002/bies.70084 ↗
AbstraktBibliografické údaje

Abstrakt

ABSTRACT TDP‐43 is a ubiquitously expressed RNA‐binding protein that aggregates in the brains of patients suffering from neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Alzheimer's disease. Aggregated TDP‐43 in these diseases is hyperphosphorylated in its C‐terminal intrinsically disordered region, while physiological TDP‐43 is normally unphosphorylated. Whether TDP‐43 phosphorylation is a pathological driver, or rather a protective antagonist of TDP‐43 aggregation and consequently neurodegeneration, is still debated and a matter of ongoing research. Here, we review current knowledge about TDP‐43 phosphorylation in disease and the kinases and phosphatases that regulate this post‐translational modification. We discuss how TDP‐43 phosphorylation is thought to shape TDP‐43's phase separation, aggregation and toxicity in neurodegenerative diseases. We highlight recent research that provides evidence that hyperphosphorylation antagonizes TDP‐43 phase separation and aggregation, and speculate about a potential role of condensates in TDP‐43 phosphorylation.

Znalosti, které odpovídají vaší práci.

Od bezplatného začátku přes osobní rešerše literatury až po kompletní Research Suite.

Zobrazit tarify →

Jsou zahrnuty všechny plné texty vydavatelů?

Ne. Bibliografické záznamy, abstrakty a plné texty jsou různé typy obsahu. To, zda je plný text dostupný, závisí na zdroji, Open Access a vašich stávajících licencích. Tarif EUVIMED nenahrazuje dodatečná vydavatelská práva.

Zobrazit tarify →